SS Innovations International (NASDAQ: SSII) announced that its SSi Mantra surgical robotic system will be featured at the 2026 Society of Robotic Surgery Annual Meeting, July 23-26 in Hollywood, Florida. The system will be displayed throughout the event, highlighted in multiple breakout sessions and used in a live broadcast of a remote partial nephrectomy performed by Dr. Amitabh Singh from the company’s headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.
Chairman and CEO Dr. Sudhir Srivastava will participate as a speaker and panelist in multiple sessions covering telesurgery, robotic surgery adoption, regulatory frameworks and global access to robotic care. As of July 6, 2026, the SSi Mantra system had been used in 12,375 procedures spanning more than 170 procedure types, including 653 cardiac procedures, 178 telesurgeries and 225 pediatric surgeries, while approximately 2,100 physicians have been trained on the platform. For more details, visit https://ibn.fm/YYYKE.
The demonstration underscores the company's progress in making robotic surgery more accessible globally. SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
This announcement is significant as it highlights the growing adoption of the SSi Mantra system and the potential for telesurgery to expand access to specialized surgical care. The live remote procedure demonstrates the system's capabilities in real-world settings and could pave the way for broader regulatory acceptance and integration into healthcare systems worldwide. For more information, please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
